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Abstract Cholesterol efflux (CE) is the initial and important
step of reverse cholesterol transport (RCT), a major protective
system against atherosclerosis. However, most of the molecular
mechanism for CE still remains to be clarified. In the present
study, cDNA subtraction revealed that the expression of a
member of the Rho GTPase family, Cdc42Hs, was markedly
decreased in both passaged fibroblasts and macrophages (MP)
from patients with Tangier disease (TD), a rare lipoprotein
disorder with reduced CE. This small G protein is known to have
many cell biological activities such as rearrangement of actin
cytoskeleton and vesicular transport, however the association
between this molecule and lipid transport has never been
reported. We demonstrate that MDCK cells expressing the
dominant negative form of Cdc42Hs had reduced CE, inversely
ones expressing the dominant active form had increased CE.
From these observations, we would like to raise a novel
hypothesis that this type of small G protein may play a role in
some steps of CE. To our knowledge, the present study is the first
demonstration that the expression of this molecule is altered in
cells from human disease. ß 2000 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Atherosclerotic cardiovascular disease is one of the major
causes of death in the well-developed countries. Reverse cho-
lesterol transport (RCT) is the formulated concept for the
protective system against atherosclerosis [1,2]. In the RCT
system, high density lipoprotein (HDL) particles are thought
to play an important role as a shuttle carrying cholesterol
from lipid-laden cells in the arterial walls to the liver, a ter-
minal of RCT, where cholesterol is catabolized and secreted
as a bile. The initial step of RCT is called ‘cholesterol e¥ux
(CE)’, where small and lipid poor HDL particles remove cho-
lesterol from the cells [3].
Enhancement of RCT, especially its initial step, CE, is one
of the novel strategies for anti-atherosclerotic treatment,
which would make it possible to regress and stabilize choles-
terol-rich plaque in the atherosclerotic lesions. However, most
of the molecular map for CE still remains to be drawn. Our
purpose is to ¢ll in such a large blank in the map for under-
standing the molecular mechanism for CE by patient- and
disease-oriented researches [4].
Tangier disease (TD), a rare lipoprotein disorder, is thought
to be a kind of model for the impairment of the ¢rst step of
the RCT system by the following reasons [5] : (a) impaired CE
from TD cells, (b) altered intracellular tra⁄cking of HDL
particles, and (c) hypercatabolism of HDL particles. Many
laboratories including ours reported the premature athero-
sclerotic coronary artery disease in some patients with TD
[6,7]. In the present study, we found that the expression of
a member of the Rho GTPase family [8,9], Cdc42Hs, was
decreased in cells from TD by cDNA subtraction technique.
2. Materials and methods
2.1. Patients
Cutaneous ¢broblasts and monocyte-derived macrophages (MP)
were obtained from two unrelated TD patients after the informed
consent: TD1 was a 56 years old male (plasma total cholesterol,
0.72 mmol/l ; triglycerides, 2.60 mmol/l ; HDL^cholesterol, 0.16
mmol/l). TD2 was a 60 years old male (plasma total cholesterol,
0.78 mmol/l ; triglyceride, 2.0 mmol/l ; HDL^cholesterol, 0.13 mmol/
l). Both patients had typical clinical symptoms such as orange tonsils,
hepatosplenomegaly, and increased levels of prepro apolipoprotein
(Apo) AI in plasma. We have recently reported that TD1 had su¡ered
from severe coronary heart diseases, demonstrated by coronary angio-
grams with intravascular ultrasoundgraphy [7]. It was reported that
many of patients with TD have mutations in the ATP-binding cassette
transporter-1 (ABCA1) gene [10^13]. The mutational analyses of
ABCA1 gene in our patients have not been completed yet in TD1,
however TD2 had a novel mutation in the ABCA1 gene (Inazu, A.
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and Mabuchi, H. et al., personal communication). For cDNA sub-
traction, we have made pooled total RNA of MP from 10 control
subjects to minimize the di¡erence of mRNA pro¢les between indi-
viduals. Control ¢broblasts were obtained from age-matched healthy
volunteers after obtaining informed consent.
2.2. Cell culture
Passaged ¢broblasts and MDCK cells were cultured according to
standard conditions. All passaged ¢broblasts cultured were used be-
tween passages 5 and 15 and after culturing for 7 days following
splitting 1:2. MP were isolated and cultured as described previously
[14].
2.3. Immuno£uorescent microscopy and antibodies used
Cells were stained and analyzed by a confocal laser microscopy
(Zeiss LSM 510, Carl Zeiss Co., Ltd.) as described previously [14].
In order to see the actin cytoskeletons, the cells were stained by Rhod-
amine-Phalloidin (Molecular Probe).
2.4. Subtraction cDNA library
cDNA subtraction was performed with PCR-select Subtraction Kit
(Clontech, Palo Alto, CA, USA) according to the manufacturer’s
recommendation. Brie£y, two cDNA pools were synthesized from
total RNA isolated from TD MP and pooled total RNA from control
MP. The cDNA pools were digested by RsaI before cDNA subtrac-
tions. cDNA from TD cells were subtracted using cDNA from control
cells and suppression subtractive hybridization was performed accord-
ing to the manufacturer’s protocol. The remaining cDNAs were ran-
domly subcloned into pGEM-T Easy vector (Promega) and se-
quenced.
2.5. Plasmid preparation and establishment of stable cell lines
expressing dominant active or negative form of Cdc42Hs
Expression vectors, pEF-BOS-myc-V12Cdc42Hs (dominant active
form of Cdc42Hs, Cdc42-DA) and pEF-BOS-myc-N17Cdc42Hs
(dominant negative form of Cdc42Hs, Cdc42-DN) were constructed
and stably expressing MDCK cells were isolated, as described [15,16].
2.6. Cholesterol e¥ux assay
Subcon£uent passaged ¢broblasts and MDCK cells were labeled
with 2 mCi/well 3H-cholesterol (NEN Life Science Products, Inc.,
Boston, MA, USA) for 24 h with 2 mg/ml of an ACAT inhibitor,
F-1394 (Fujirebio, Tokyo, Japan) in serum-free medium supplemented
with 0.1% BSA. After equilibration, cholesterol e¥ux from the cells
was carried out for the indicated hours to a 0.1% BSA serum-free
medium with and without Apo AI (Sigma) to measure Apo AI-spe-
ci¢c e¥ux. Cell supernatants were collected and monolayers were
lysed in 0.1 M NaOH. Radioactivity was determined by liquid scin-
tillation counting. The percentage e¥ux is the ratio of counts in the
supernatant to the sum of radioactivities in the media plus superna-
tant. Each experiment was carried out in quadruplicate.
3. Results and discussion
3.1. The cDNA subtraction technique reveals the decreased
expression of Cdc42Hs in cells from patients with Tangier
disease
We have performed cDNA subtraction with using total
RNA from MP from TD1, showing that the expression of
cDNA encoding Cdc42Hs (GenBank Accession Number
M57298) [8,9] was decreased in MP of TD1, compared with
pooled RNA from healthy volunteers (Fig. 1A). Reverse tran-
scription-based polymerase chain reaction (RT-PCR) analyses
con¢rmed that mRNA expression of Cdc42Hs was decreased
in macrophages (MP) obtained from the other patient, TD2,
Fig. 1. Decreased expression of Cdc42Hs in cells from patients with Tangier disease. A: 10 Wg of total RNA from macrophages (MP) from
TD1 and pooled total RNA from control MP were subjected to Northern blot analysis. Biotinylated 576 nt human Cdc42Hs cRNA probes
corresponding to nt 70^645 human Cdc42Hs cDNA (GenBank Accession Number M57298) and GAPDH 316 nt cRNA probes transcribed
from pTRI-GAPDH Human (Ambion) were used as probes. B: Whole cell lysates were extracted from human MP cultured in 10% human AB
serum/RPMI. 20 Wg of whole cell lysates were separated by 5^15% SDS^PAGE and transferred to PVDF membranes. The membranes were in-
cubated with anti-Cdc42 antibody (Cat. # sc-87, Santa Cruz) and IgG bound was visualized by ECL plus kit (Amersham). C and D: Whole
cell lysates were extracted from ¢broblasts of TD1 and TD2 and two control ¢broblasts and subjected to Western blot analysis. The immunore-
active mass of GAPDH was detected with anti-GAPDH antibody (Cat. # A9521, Sigma) and shown as an internal standard. The exposed ¢lms
were subjected to NIH image programs. Bar graph (D) shows the abundance of immunoreactive mass of Cdc42Hs in TD, comparing with that
in control.
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as well (data not shown). Western blot analyses showed that
the immunoreactive masses of Cdc42Hs were also decreased
in both MP (Fig. 1B) and ¢broblasts (Fig. 1C and D) ob-
tained from both TD1 and TD2. These results indicated
that the expression of this type of small G protein was mark-
edly decreased in both MP and passaged ¢broblasts from two
unrelated TD patients. Cdc42 belongs to a small G protein,
Rho GTPase family. There are two isoforms of this molecule;
Cdc42Hs is ubiquitous and Cdc42G25K is in neuron-speci¢c
form. Many experimental studies revealed that this G protein
has a variety of cell biological functions, however relevance
and signi¢cance of this molecule in human diseases and
pathological conditions is not known yet. To our knowledge,
this is the ¢rst demonstration that the expression of this mol-
ecule is altered in cells from human disease.
3.2. Alteration of actin cytoskeletons in cells from Tangier
disease
Many experimental studies using dominant active or nega-
tive form of Cdc42 have demonstrated that Cdc42 functions
to regulate rearrangement of actin cytoskeleton as well as
formation of ¢lopodia in cell lines including some ¢broblasts
and MP [8,9]. Therefore, we have stained F-actin by Rhod-
amine^Phalloidin in both passaged ¢broblasts and monocyte-
derived MP obtained from Tangier patients and controls, in
order to know whether or not the TD cells have the alteration
Fig. 2. Abnormal cell shape of ¢broblasts (B and D) and macrophages (F) from patients with Tangier disease. Fibroblasts (panels A, B, C,
and D) and macrophages (panels E and F) were incubated in a 2-well glass chamber slide (FALCON culture slide; Becton Dickinson Labware,
Franklin Lakes, NJ, USA). Normal cells were demonstrated in panels A, C, and E. Cells from TD1 were shown in panels B, D, and F. The
cells were stained by Rhodamine^Phalloidin (Molecular probes) to visualize F-actin. Images were acquired by confocal laser microscopy as a
single 1 Wm thick optical section using a Zeiss LSM 410 confocal microscope. The magnitude for each image was as follows: A and B, 10Uob-
jective. C, 100Uobjective. D, 40Uobjective. E and F, 100Uobjective.
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of actin cytoskeletons. As shown in Fig. 2, lower power view
of confocal laser microscopy showed that ¢broblasts from
TD1 (Fig. 2) were larger in size, as reported previously [17].
TD ¢broblasts appeared to have coarse actin ¢bers (Fig. 2B),
compared to those from normal controls (Fig. 2A). Higher
power view showed that the edge of cells are sharp in TD
cells (Fig. 2D), whereas control cells had some spike forma-
tions (Fig. 2C). MP from TD1 (Fig. 2F) also had apparent
abnormal cell shape with less ¢lopodia formation than those
from controls (Fig. 2E). Both ¢broblasts and MP from TD2
had similar morphological changes to those of TD1 (data not
shown). These observations showed that the TD cells with
decreased expression of endogenous Cdc42Hs had abnormal
actin cytoskeletons with less ¢lopodia formation, which was
similar to those observed in cells expressing the dominant
negative form of Cdc42 [8,9]. These data suggested that the
altered expression of Cdc42Hs might in some parts contribute
to the abnormal actin cytoskeletons in TD cells.
3.3. Cholesterol e¥ux was altered in MDCK cells expressing
the dominant negative or active form of Cdc42Hs
In order to search for the possibility that the decreased
expression of Cdc42Hs may be related to impaired CE, we
have tested CE from the MDCK cells stably expressing dom-
inant active or negative form of Cdc42Hs, which have been
developed by us [15,16]. As shown in previous reports, Apo
AI-mediated CE was markedly decreased in TD cells (Fig.
3A) [5,6]. It was very interesting that Apo AI-mediated CE
is increased from cells expressing Cdc42-DA. Inversely, the
CE was signi¢cantly decreased in cells expressing Cdc42-DN
(Fig. 3B).
3.4. A novel hypothesis that Cdc42Hs may play a role in some
process of cholesterol e¥ux
CE from the cells is thought to be a very complicated pro-
cess. However, it can be divided at least into the following two
steps: movement of cholesterol from some intracellular lesions
to plasma membrane and release of cholesterol to the accep-
tors such as small HDL particles or free Apo AI [18]. It is
obvious that the ABCA1 gene product is one of the major
gate keeper molecules for CE, however other molecules
should be involved in the process of CE [11]. We have found
that scavenger receptor class B type I (SR-BI) [19], which has
an ability to mediate CE, was expressed in the foam cells in
the human atherosclerotic lesions [14]. Furthermore, we could
purify a GPI-anchored protein on the cell surface of human
monocyte-derived MP, which might be involved in CE [20].
Cdc42 was originally identi¢ed as a factor necessary for the
budding of yeast and reported to be the brefeldin A-sensitive
component located in the Golgi apparatus as well as plasma
membrane in some mammalian cells [21]. Recently it has been
suggested that Cdc42 may control vesicular transport and
secretory transport in some cells [22]. We had speculated
that vesicular transport might be involved in intracellular
movement of cholesterol in association with rearrangement
of actin cytoskeletons. Considering the present results with
MDCK cells expressing mutants of Cdc42Hs (Fig. 3), we
have raised a novel hypothesis that this type of small G pro-
tein may be one of the important components for intracellular
lipid transport and subsequent CE from the cells. Further
studies are going on in our laboratory to elucidate signi¢cance
of Cdc42Hs in these processes of CE as well as the develop-
ment of atherosclerosis.
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